AbelZeta Pharma

Our Leadership

At AbelZeta we are committed to developing novel immune cell therapies to address cancerous and inflammatory & immunological diseases.

TONY (BIZUO) LIU

Chairman and CEO

Mr. Tony Bizuo Liu joined our Group in February 2013 as a director and a member of an audit committee of AbelZeta Inc.. He was our chief financial officer and secretary between January 2014 and January 2016, and has been our chief executive officer since February 2016. Mr. Liu was appointed as a Director and the chairman of our Board on January 3, 2021. He is primarily responsible for overseeing overall management, business and strategies, strategic financial planning and financial management of our Group. Further, Mr. Liu is currently a director and/or a senior management member of our certain subsidiaries.

Prior to joining our Group, Mr. Liu spent 19 years at Microsoft Corporation, a multinational technology conglomerate listed on the Nasdaq Stock Market (stock symbol: MSFT), where he served in a variety of finance leadership roles. He previously held senior positions at Alibaba Group Holding Limited (阿里巴巴集團控股有限公司) (“Alibaba Group”), a multinational technology company listed on the New York Stock Exchange (stock symbol: BABA) and the Hong Kong Stock Exchange (stock code: 9988 (HKD Counter) and 89988 (RMB Counter)), where he was primarily responsible for financial matters, investments and strategies.

Mr. Liu obtained his bachelor’s degree in physics from Soochow University (蘇州大學) in Jiangsu in July 1986. He has been certified by the Washington State Board of Accountancy as a certified public accountant in the State of Washington in the United States since 1992.

YIHONG YAO, PHD, BS

CHIEF SCIENTIFIC OFFICER

Dr. Yihong Yao joined our Group in June 2015, and has been our chief scientific officer since then. He is primarily responsible for overseeing our clinical pipeline and strategies, and daily management of our Rockville center.

Prior to joining our Group, from February 2001 to April 2005, Dr. Yao was a senior scientist of translational science at Abbott Bioresearch Center, the local Massachusetts site of Abbott Laboratories, where he was primarily responsible for research on translational science. From May 2005 to July 2015, he was a director and the head of pharmacogenomics and bioinformatics at the translational sciences department of MedImmune, Inc., a biologics R&D arm of AstraZeneca, where he was primarily responsible for overseeing the pharmacogenomics group of the company.

Dr. Yao obtained his bachelor’s degree in biochemistry from Fudan University (復旦大學) in Shanghai. He obtained his doctor’s degree in biology (biochemistry) from the University of Kansas in the United States in August 1996. Besides, he obtained his master’s degree in bioinformatics from Boston University in the United States in May 2004

ANDREW CHAN, JD, MBA

CHIEF LEGAL OFFICER

Mr. Andrew K Chan joined our Group in February 2011 as our chief legal officer, chief financial officer and company secretary. He has been our chief legal officer and company secretary since July 2020. He is primarily responsible for overseeing overall management, legal affairs and strategies of our Group.

Mr. Chan obtained his bachelor’s degree in management from Embry-Riddle Aeronautical University in the United States in August 1982. He obtained his master of business administration degree with concentration in computer system management and operations research from Nova University in the United States in April 1987. Mr. Chan further obtained his Juris Doctor degree from South Texas College of Law in the United States in May 1995. Mr. Chan is currently a member of the State Bar of Arizona.

MICHAEL HAVERT, PHD

SENIOR VICE PRESIDENT, REGULATORY AFFAIRS & PROGRAM HEAD, US

JIAQI HUANG, MD, PHD

SENIOR VICE PRESIDENT, TRANSLATIONAL MEDICINE

MATTHEW MANDEL, MD

SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT, AUTOIMMUNE, GLOBAL

ZHU DAN JUDY, MD

VICE PRESIDENT, CLINICAL DEVELOPMENT, HEMATOLOGY & AUTOIMMUNE, CHINA

ZOU AN ANDY, PHD

VICE PRESIDENT, NGCT (NEXT GENERATION CELL THERAPY)

HONG YI, PHD

VICE PRESIDENT, TECHNOLOGY

ZOU AN ANDY, PHD

VICE PRESIDENT, NGCT (NEXT GENERATION CELL THERAPY)

Scroll to Top